STK-001, STK-001
STK-001-DS-301
Phase 3 small_molecule active
Quick answer
STK-001, STK-001 for Dravet syndrome is a Phase 3 program (small_molecule) at Stoke Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Stoke Therapeutics
- Indication
- Dravet syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active